Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-024436
Filing Date
2025-05-12
Accepted
2025-05-12 07:03:13
Documents
73
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q avtx-20250331.htm   iXBRL 10-Q 902060
2 EX-31.1 ex-3111q2025.htm EX-31.1 10535
3 EX-31.2 ex-3121q2025.htm EX-31.2 10324
4 EX-32.1 ex-3211q2025.htm EX-32.1 11095
10 GRAPHIC avtx-20250331_g1.jpg GRAPHIC 215961
  Complete submission text file 0001628280-25-024436.txt   7087613

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20250331.xsd EX-101.SCH 57140
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avtx-20250331_cal.xml EX-101.CAL 62596
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20250331_def.xml EX-101.DEF 334042
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20250331_lab.xml EX-101.LAB 691868
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20250331_pre.xml EX-101.PRE 509384
76 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20250331_htm.xml XML 720086
Mailing Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087
Business Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37590 | Film No.: 25932542
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)